For over a decade, the standard of care for high-risk MDS has remained a class of drugs called hypomethylating agents (HMAs).
Phase II study of pevonedistat (P) + azacitidine (A) versus A in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML), or low-blast acute myelogenous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results